Literature DB >> 17064963

Defining COPD exacerbations: impact on estimation of incidence and burden in primary care.

John F O'Reilly1, Angela E Williams, Kay Holt, Leanne Rice.   

Abstract

AIMS: To investigate the impact of definition on the incidence of chronic obstructive pulmonary disease (COPD) exacerbations in primary care.
METHODS: In a one-year prospective, observational study, data from diary cards were used to determine the incidence of symptom- and healthcare-defined exacerbations. One hundred and twenty seven patients completed > or =80% of days in the diary card and were included in the analysis.
RESULTS: Incidence of COPD exacerbation varied according to definition. Mean yearly rates were 2.3 for symptom- and 2.8 for healthcare-defined exacerbations. Although patients with FEV(1) <50% had a higher mean yearly rate of healthcare-defined exacerbations than those with FEV(1) > or =50% (3.2 vs 2.3; p=0.003), patients with less severe disease reported recurrent exacerbations. There was limited agreement between symptom- and healthcare-defined exacerbations.
CONCLUSION: Lung function does not appear to be a valid criterion for assigning COPD management directed at patients with recurrent exacerbation.

Entities:  

Mesh:

Year:  2006        PMID: 17064963      PMCID: PMC6730839          DOI: 10.1016/j.pcrj.2006.08.009

Source DB:  PubMed          Journal:  Prim Care Respir J        ISSN: 1471-4418


  22 in total

1.  Trends in Outcomes, Financial Burden, and Mortality for Acute Exacerbation of Chronic Obstructive Pulmonary Disease (COPD) in the United States from 2002 to 2010.

Authors:  Chetna Jinjuvadia; Raxitkumar Jinjuvadia; Chaitanya Mandapakala; Navin Durairajan; Suthat Liangpunsakul; Ayman O Soubani
Journal:  COPD       Date:  2016-07-15       Impact factor: 2.409

2.  Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Authors:  Robert A Wise; Russell A Acevedo; Antonio R Anzueto; Nicola A Hanania; Fernando J Martinez; Jill A Ohar; Donald P Tashkin
Journal:  Chronic Obstr Pulm Dis       Date:  2016-11-15

Review 3.  Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease.

Authors:  Maxwell Howcroft; E Haydn Walters; Richard Wood-Baker; Julia Ae Walters
Journal:  Cochrane Database Syst Rev       Date:  2016-12-19

4.  The effect of quitting smoking on costs and healthcare utilization in patients with chronic obstructive pulmonary disease: a comparison of current smokers versus ex-smokers in routine clinical practice.

Authors:  Antoni Sicras-Mainar; Javier Rejas-Gutiérrez; Ruth Navarro-Artieda; Jordi Ibáñez-Nolla
Journal:  Lung       Date:  2014-05-10       Impact factor: 2.584

Review 5.  Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium.

Authors:  Donald P Tashkin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-02-18

6.  Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD.

Authors:  Joseph Seaman; Anthony C Leonard; Ralph J Panos
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-04-07

Review 7.  Variability of the chronic obstructive pulmonary disease key epidemiological data in Europe: systematic review.

Authors:  Kokuvi Atsou; Christos Chouaid; Gilles Hejblum
Journal:  BMC Med       Date:  2011-01-18       Impact factor: 8.775

Review 8.  Association between lung function and exacerbation frequency in patients with COPD.

Authors:  Martine Hoogendoorn; Talitha L Feenstra; Rudolf T Hoogenveen; Maiwenn Al; Maureen Rutten-van Mölken
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-12-09

9.  Clinical diaries in COPD: compliance and utility in predicting acute exacerbations.

Authors:  E Haydn Walters; Julia Walters; Karen E Wills; Andrew Robinson; Richard Wood-Baker
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-07-10

10.  The clinical and economic burden of chronic obstructive pulmonary disease in the USA.

Authors:  Anthony J Guarascio; Shauntá M Ray; Christopher K Finch; Timothy H Self
Journal:  Clinicoecon Outcomes Res       Date:  2013-06-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.